- RecruitingTherapeutic use (Phase IV)
Evaluation of the effect of tacrolimus on carbohydrate metabolism in pre-renal transplantation dialysis patients
This study looks at how a medicine called tacrolimus might affect blood sugar levels in people with kidney failure who are on dialysis, before they have a kidney transplant. Researchers want to see if there are any changes in blood sugar after 14 days of taking the medicine.
For: HemodialysisFrance - RecruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
This study is looking at a new medicine called frexalimab for adults having a kidney transplant. It compares frexalimab to a standard medicine, tacrolimus, to see if it's safe and works well to prevent the body rejecting the new kidney.
For: Kidney Transplant RejectionUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
This study looks at a new drug, felzartamab, for Primary Membranous Nephropathy (PMN), a kidney disease. Researchers compare it to an existing treatment, tacrolimus, to see how well it works in reducing protein in urine and improving kidney health.
For: Primary Membranous NephropathyUnited States · Argentina · Australia - Active not recruitingPHASE2
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
This study looks at whether giving a medicine called tacrolimus to organ donors who have sadly passed away can help transplanted kidneys work better. Researchers want to see if this medicine can stop transplant problems and make organs last longer for people receiving them.
For: Organ Transplant Failure or Rejection · Brain Death · Ischemic Reperfusion InjuryCanada - Active not recruitingPHASE2
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
This study looks at a new drug, BIVV020, to help people who have had a kidney transplant. It aims to see if it can stop their body from rejecting the new kidney or treat rejection if it happens. The study tests how well it works and if it's safe.
For: Transplant RejectionUnited States · Canada · France - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
This study is looking at a new treatment called Obinutuzumab for a kidney condition called primary membranous nephropathy (pMN). It's a Phase 3 study, meaning it's well into testing, to see if this new medicine works better and is safer than current treatments.
For: Primary Membranous NephropathyUnited States · Argentina · Brazil - RecruitingPHASE2, PHASE3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
This study is testing a new medicine, povetacicept, for people with a kidney condition called primary membranous nephropathy (pMN). It aims to see how well it works, if it's safe, and if people can tolerate it compared to another treatment, tacrolimus.
For: Primary Membranous NephropathyUnited States · Australia · Brazil - Active not recruitingPHASE2, PHASE3
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
This study is testing a new medicine called zanubrutinib for people with a kidney condition called primary membranous nephropathy. It compares zanubrutinib with a standard medicine, tacrolimus, to see how well it reduces protein in the urine and helps people get better.
For: Primary Membranous NephropathyUnited States · Brazil · Canada - RecruitingPHASE3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
This study compares two ways to help young people (12-17) after a kidney transplant. It looks at changing medicine from one type (calcineurin inhibitor) to another (belatacept-based) and how well patients stick to their treatment. It aims to see which approach works best.
For: Renal Allograft RecipientsUnited States · Argentina · Belgium - Enrolling by invitationPHASE2
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
This study looks at the long-term safety and effectiveness of a new drug, tegoprubart (also called AT-1501), compared to a standard drug, tacrolimus. It's for people who have had a kidney transplant to help prevent their body from rejecting the new kidney.
For: Kidney Transplant RejectionUnited States · Australia · Brazil